Genotoxic evaluation of selective serotonin-reuptake inhibitors by use of the somatic mutation and recombination test in Drosophila melanogaster

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 748, Issue 1-2, 2012, Pages 17-20

  Gürbüzel, Mehmet ^a   Oral, Elif ^b   Kizilet, Halit ^c   Halici, Zekai ^b   Gulec, Mustafa ^b  

^a ERZINCAN UNIVERSITY   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

^c ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Citalopram; Drosophila melanogaster; Genetic toxicology; Sertraline; Wing spot test

Indexed keywords

4 AMINOPHENOL; CITALOPRAM; SELECTRA; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME 3; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DROSOPHILA MELANOGASTER; GENOTOXICITY; HETEROZYGOSITY; MITOTIC RECOMBINATION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SOMATIC CROSSING OVER; SOMATIC MUTATION; SOMATIC MUTATION AND RECOMBINATION TEST;

ANIMALS; ANTIDEPRESSIVE AGENTS; DNA DAMAGE; DROSOPHILA MELANOGASTER; MUTAGENICITY TESTS; MUTAGENS; SEROTONIN UPTAKE INHIBITORS;

DROSOPHILA MELANOGASTER;

EID: 84865020265     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2012.06.004     Document Type: Article

References (40)

1. Hyttel J., Arnt J., Sanchez C. The pharmacology of citalopram. Rev. Contemp. Pharmacother. 1995, 6:271-285.
2. Rochat B., Amey M., Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther. Drug Monit. 1995, 17:273-279.
3. Baumann P., Larsen F. The pharmacokinetics of citalopram. Rev. Contemp. Pharmacother. 1995, 6:287-295.
4. L. Biochem. Pharmacol. 1999, 57:1199-1208.
5. Snyder R.D., Ewing D., Hendry L.B. DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat. Res. 2006, 609:47-59.
6. Atmaca M., Tezcan E., Kuloglu M., Ustundag B., Tunckol H. Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur. Arch. Psy. Clin. N. 2004, 254:231-235.
7. Henry T.B., Kwon J., Armbrust K.L., Black M.C. Acute and chronic toxicity of five selective serotonin reuptake inhibitors in Ceriodaphnia dubia. Environ. Toxicol. Chem. 2004, 23:2229-2233.
8. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 2004, 58:744-747.
9. Koe B.K., Weissman A., Welch W.M., Browne R.G. Sertraline, lS,4S-sN methyl-4-(3,4-dichlorophenylf-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol. Exp. Ther. 1983, 226:686-700.
10. Murdoch D., McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992, 44:604-624.
11. Davies T.S., Kluwe W.M. Preclinical toxicological evaluation of sertraline hydrochloride. Drug. Chem. Toxicol. 1998, 21:163-179.
12. Liston H.L., DeVane C.L., Boulton D.W., Risch S.C., Markowitz J.S., Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J. Clin. Psychopharm. 2002, 22:169-173.
13. Andreazza A.C., Frey B.N., Erdtmann B., Salvador M., Rombaldi F., Santin A., Gonçalves C.A., Kapczinski F. DNA damage in bipolar disorder. Psychiat. Res. 2007, 153:27-32.
14. Graf U., Abraham S.K., Guzmán-Rincón J., Würgler F.E. Antigenotoxicity studies in Drosophila melanogaster. Mutat. Res. 1998, 402:203-209.
15. Ramel C., Magnusson J. Modulation of genotoxicity in Drosophila. Mutat. Res. 1992, 267:221-227.
16. Frei H., Würgler F.E. Induction of somatic mutation and recombination by four inhibitors of eukaryotic topoisomerases assayed in the wing spot test of Drosophila melanogaster. Mutagenesis 1996, 11:315-325.
17. Lindsley D.L., Zimm G.G. The Genome of Drosophila melanogaster 1992, Academic Press, San Diego, CA.
18. Frei H., Würgler F.E. Statistical methods to decide whether mutagenicity test data from Drosophila assays indicate a positive, negative or inconclusive result. Mutat. Res. 1988, 203:297-308.
19. Kastenbaum M.A., Bowman K.O. Tables for determining the statistical significance of mutation frequencies. Mutat. Res. 1970, 9:527-549.
20. Szabad J., Soos I., Polgar G., Hejia G. Testing the mutagenicity of malondialdehyde and formaldehyde by the Drosophila mosaik and the sexlinked recessive letal test. Mutat. Res. 1983, 113:117-133.
21. Graf U., Würgler F.E., Katz A.J., Frei H., Juon H., Hall C.B., Kale P.G. Somatic mutation test in Drosophila melanogaster. Environ. Mol. Mut. 1984, 6:153-188.
22. Guzmán-Rincón J., Graf U. Drosophila melanogaster somatic mutation and recombination test as a biomonitor. Biomonitors and Biomarkers as Indicators of Environmental Change. 1995, 169-181. Plenum Press, New York. F.M. Butterworth, L.D. Corkum, J. Guzmán- Rincón (Eds.).
23. Bendele R.A., Adams E.R., Hoffman W.P., Gries C.L., Morton D.M. Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res. 1992, 52:6931-6935.
24. Bozkurt G., Abay E., Ates I., Karabogaz G., Ture M., Savran F.O., Palanduz S., Temocin K., Algunes C. Clastogenicity of selective serotonin-reuptake inhibitors. Mutat. Res. 2004, 558:137-144.
25. Vogel E.W., Zijlstra J.A. Mechanistic and methodological aspects of chemically-induced somatic mutation and recombination in Drosophila melanogaster. Mutat. Res. 1987, 182:243-264.
26. Würgler F.E., Vogel E.W. In vivo mutagenicity testing using cells of Drosophila melanogaster. Chemical Mutagens, Principles and Methods for their detection 1986, 1-72. Plenum Press, New York. F.J. De Serres (Ed.).
27. Kaya B., Yanikoĝlu A., Creus A., Marcos R. Genotoxicity testing of five herbicides in the Drosophila wing spot test. Mutat. Res. 2000, 465:77-84.
28. Valadares B.L.B., Graf U., Spanó M.A. Inhibitory effects of water extract of propolis on doxorubicin induced somatic mutation and recombination in Drosophila melanogaster. Food Chem. Toxicol. 2008, 46:1103-1110.
29. Munoz-Bellido J.L., Munoz-Criado S., Garcìa-Rodrìguez J.A. Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors. Int. J. Antimicrob. Agents 2000, 14:177-180.
30. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 1993, 24:203-220.
31. Tamam L., Ozpoyraz N. Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv. Ther. 2002, 19:17-26.
32. Kusakawa S., Yamauchi J., Miyamoto Y., Sanbe A., Tanoue A. Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system. Life Sci. 2008, 83:871-877.
33. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 1996, 335:1010-1015.
34. Ellfolk M., Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod. Toxicol. 2010, 30:249-260.
35. Sloot W.N., Bowden H.C., Yih T.D. In vitro and in vivo reproduction toxicology of 12 monoaminergic reuptake inhibitors: possible mechanisms of infrequent cardiovascular anomalies. Reprod. Toxicol. 2009, 28:270-282.
36. van Schaik N., Graf U. Genotoxicity evaluation of five tricyclic antidepressants in the wing somatic mutation and recombination test in Drosophila melanogaster. Mutat. Res. 1991, 260:99-104.
37. van Schaik N., Graf U. Structure-activity relationships of tricyclic antidepressants and related compounds in the wing somatic mutation and recombination test of Drosophila melanogaster. Mutat. Res. 1993, 286:155-163.
38. Franco C.C.S., Castro-Prado J., Rosada L.J., Sant'Anna J.R., Castro-Prado M.A.A. Mitotic recombination: a genotoxic effect of the antidepressant citalopram in Aspergillus nidulans. Exp. Biol. Med. 2010, 235:1257-1262.
39. Physicians' Desk Reference, 59th ed., Thomson PDR, Montvale, NJ, USA, 2005.
40. Steingart A.B., Cotterchio M. Do antidepressants cause, promote, or inhibit cancers?. J. Clin. Epidemiol. 1995, 48:1407-1412.